$141m Hong Kong IPO to help build Consun's R&D
This article was originally published in Scrip
Executive Summary
Consun Pharmaceutical is set to raise up to HKD1.09bn ($140.6m) in an initial public offering in Hong Kong after pricing the shares at the top end of the proposed range.